絞り込み

16762

広告

院内トリアージ実施料の範囲を拡大へ (日経BP)

2020年4月8日、中央社会保険医療協議会(中医協)総会が開催され、新型コロナウイルス感染症に伴う医療保険制度の対応が議論された。 厚生労働省保険局医療課は、外...

  1. 「第4の携帯」楽天が船出 コロナで一部店...
  2. ペムブロリズマブのTMB高値既治療固形癌...
  3. 中等症の患者を集めて高次病院の負担軽減目...
  4. 令和2年3月末申請の収容定員の増加に係る...

ニュース一覧

The Italian Registry of Endovascular Treatment in Acute Stroke: rationale, design and baseline features of patients.

著者 Mangiafico S , Pracucci G , Saia V , Nencini P , Inzitari D , Nappini S , Vallone S , Zini A , Fuschi M , Cerone D , Bergui M , Cerrato P , Gandini R , Sallustio F , Saletti A , De Vito A , Romano DG , Tassi R , Causin F , Baracchini C , Piano M , Motto C
Neurol Sci.2015 Jan 8 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (10view , 0users)

Full Text Sources

Medical

Endovascular treatment (ET) showed to be safe in acute stroke, but its superiority over intravenous thrombolysis is debated. As ET is rapidly evolving, it is not clear which role it may deserve in the future of stoke treatments. Based on an observational design, a treatment registry allows to study a broad range of patients, turning into a powerful tool for patients' selection. We report the methodology and a descriptive analysis of patients from a national registry of ET for stroke. The Italian Registry of Endovascular Treatment in Acute Stroke is a multicenter, observational registry running in Italy from 2010. All patients treated with ET in the participating centers were consecutively recorded. Safety measures were symptomatic intracranial hemorrhage, procedural adverse events and death rate. Efficacy measures were arterial recanalization and 3-month good functional outcome. From 2008 to 2012, 960 patients were treated in 25 centers. Median age was 67 years, male gender 57 %. Median baseline NIHSS was 17. The most frequent occlusion site was Middle cerebral artery (46.9 %). Intra-arterial thrombolytics were used in 165 (17.9 %) patients, in 531 (57.5 %) thrombectomy was employed, and 228 (24.7 %) patients received both treatments. Baseline features of this cohort are in line with data from large clinical series and recent trials. This registry allows to collect data from a real practice scenario and to highlight time trends in treatment modalities. It can address unsolved safety and efficacy issues on ET of stroke, providing a useful tool for the planning of new trials.
PMID: 25567080 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード